Currently, there are 207.16M common shares owned by the public and among those 149.37M shares have been available to trade.
The company’s stock has a 5-day price change of -8.84% and 102.45% over the past three months. ADVM shares are trading 119.18% year to date (YTD), with the 12-month market performance up to 119.71% higher. It has a 12-month low price of $0.68 and touched a high of $2.97 over the same period. ADVM has an average intraday trading volume of 2.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.16%, 5.54%, and 17.02% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Adverum Biotechnologies Inc (NASDAQ: ADVM) shares accounts for 33.33% of the company’s 207.16M shares outstanding.
It has a market capitalization of $341.81M and a beta (3y monthly) value of 0.86. The earnings-per-share (ttm) stands at -$1.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.71% over the week and 9.73% over the month.
Analysts forecast that Adverum Biotechnologies Inc (ADVM) will achieve an EPS of -$0.25 for the current quarter, -$0.19 for the next quarter and -$0.74 for 2025. The lowest estimate earnings-per-share for the quarter is -$0.33 while analysts give the company a high EPS estimate of -$0.14. Comparatively, EPS for the current quarter was -$0.29 a year ago. Earnings per share for the fiscal year are expected to increase by 46.84%, and 3.24% over the next financial year.
Looking at the support for the ADVM, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on July 07, 2022, with the firm’s price target at $4. SVB Leerink was of a view on May 03, 2021 that the stock is Mkt Perform, while Truist gave the stock Hold rating on April 29, 2021, issuing a price target of $30- $9. RBC Capital Mkts on their part issued Sector Perform rating on April 29, 2021.
